Development of sensitive molecular viral assays to screen anti-SARS-CoV-2 formulations

Description

The CASE PhD studentship provides an exciting and innovative collaboration between the University of Liverpool and Unilever to develop novel assays to monitor the anti-SARS-CoV-2 activity of newly developed products. Unilever are world leaders in developing personal care and household products which should preferentially incorporate components vital to health. The recent COVID-19 pandemic has highlighted the necessity to specifically develop products with the capacity to neutralise or destroy SARS-CoV-2, the causative virus of the disease. New products would typically be tested using live replication competent virus and assays able to monitor reduction in virus infection and/or replication. At the University of Liverpool, we utilise pseudo-typed viral particles to monitor viral infection and interactions with cells. These non-replicative particles will enable development of assays that eliminate the requirement to test new products using replicative virus, thereby minimising laboratory CL3 capacity and cost. For translation to industrial high through-put screening of formulations this is essential. The aim of this project is to develop anti-SARS-CoV-2 assays using pseudo-typed viral particles, developing means of quantifying antiviral activity through use of fluorescently labelled viral particles or assays which are tagged with easily identifiable DNA/RNA molecular probes for monitoring their structural integrity or infectivity. Working with Unilever, the project then aims to develop a high throughput protocol to enable Unilever product formulations to be tested.

The project will provide the student with a complementary project allowing them to develop and hone their molecular skills towards developing a technology with translatable potential and in a subject area of immense and timely importance. The strong collaboration between the University of Liverpool and Unilever will enable the student to bridge the gap between basic academic science and translation to state-of-the-art technologies to monitor anti-viral products in an industrial setting. The main virus of study will be SARS-CoV-2 but the technologies will be applicable for monitoring other known viruses or emerging viruses of the future. The aim is to develop a fast and sensitive high-throughput assay for monitoring antiviral potential of product formulations. The student will gain invaluable experience not just in assay development but in understanding the numerous processes and undertakings in bringing a product to testing and development in a large-scale industrial company.

Informal enquiries may be made to 

HOW TO APPLY 

Applications should be made by emailing  with a CV and a covering letter, including whatever additional information you feel is pertinent to your application; you may wish to indicate, for example, why you are particularly interested in the selected project/s and at the selected University. Applications not meeting these criteria will be rejected. We will also require electronic copies of your degree certificates and transcripts.

In addition to the CV and covering letter, please email a completed copy of the NLD BBSRC DTP Studentship Application Details Form (Word document) to , noting the additional details that are required for your application which are listed in this form. A blank copy of this form can be found at: https://www.nld-dtp.org.uk/how-apply.

Availability

Open to students worldwide

Funding information

Funded studentship

Studentships are funded by the Biotechnology and Biological Sciences Research Council (BBSRC) for 4 years. Funding will cover tuition fees at the UK rate only, a Research Training and Support Grant (RTSG) and stipend. We aim to support the most outstanding applicants from outside the UK and are able to offer a limited number of bursaries that will enable full studentships to be awarded to international applicants. These full studentships will only be awarded to exceptional quality candidates, due to the competitive nature of this scheme.

Supervisors

References

1. Human leucocyte antigen-G (HLA-G) 3’ UTR genetic polymorphisms associate with HIV-1 high-risk seronegative status in the Amsterdam Cohorts Studies. J HIV AIDS Infect Dis 7: 1-12.
2. Schistosoma mansoni soluble egg antigen (SEA) and recombinant omega-1 modulate induced CD4+ T-lymphocyte responses and reduce HIV-1 susceptibility in vitro. PLoS Pathogens (2019) 15:e1007924.
3. Blood CXCR3+ CD4 T cells are enriched in inducible replication competent HIV in aviremic antiretroviral therapy-treated individuals. Frontiers in Immunology (2018) 5:144.
4. Detection, characterisation and enrolment of donors of Ebola convalescent plasma in Sierra Leone. Transfusion (2018) 58:1289-98.
5. Comparative analysis and generation of a robust HIV-1 DNA quantification assay. Journal of Virological Methods (2018) 263:24-31.
6. Temporal and spatial analysis of the 2014-2015 Ebola virus outbreak in West Africa. Nature (2015) 52497-101.
7. HIV-1 autologous antibody neutralization associates with mother to child transmission. PLoS ONE (2013) 8:e69274.
8. Quantitation of HIV-1 DNA with a sensitive TaqMan assay that has broad subtype specificity. Journal of Virological Methods (2013) 187:94-102.
9. Altered dynamics and differential infection profiles of lymphoid and myeloid cell subsets during acute and chronic HIV-1 infection. Journal of Leukocyte Biology (2011) 89:785-795.
10. Efficient capture of antibody neutralized HIV-1 by cells expressing DC-SIGN and transfer to CD4+ T lymphocytes. Journal of Immunology (2007) 177:3177-3185.